⚠ ZYN ULTRA and a Cheaper PouchModerate threat

Philip Morris International (PM) — threat to the moat

ZYN answered competition with more pouches per can, and the American gross margin fell six points in a quarter.

PMI's response to pouch competition has been to lower the effective price. In June 2026 it launched ZYN ULTRA, in 9mg and 11mg strengths, with 20 pouches per can and a lower price per pouch1, and it planned to move its 3mg and 6mg dry ZYN to 20 pouches per can in the fourth quarter2.

U.S. segment adjusted gross margin (%)69.2202565.4Q2 2026PMI recast schedules, 8-K March 2026; Q2 2026 results release
Down 6 points in a year.

The margin effect is already visible. The American segment's adjusted gross margin was 65.4% in the second quarter of 2026, down 6.0 points3, and segment gross profit fell 9.2% to $555 million on revenue down 0.7%4.

A leader that cuts price per unit to hold share is conceding that its brand alone no longer holds it. That is the difference between ZYN and Marlboro, which raises prices every year.

The margin fall is also visible in gross profit. The segment's gross profit in the first half of 2026 was $935 million, down 27.9%5, a steeper fall than revenue's 16.1%6. Destocking explains part of the revenue decline; it does not explain why each dollar of revenue now earns less.

What would confirm this is a second quarter of falling American gross margin after the new can sizes are in place. A margin back toward 70% would mean the price move bought volume; one stuck near 65% would mean it bought nothing but a lower price.

References
  1. ReportedIn June 2026 it launched ZYN ULTRA, in 9mg and 11mg strengths, with 20 pouches per can and a lower price per pouch, and it planned to move its 3mg and 6mg dry ZYN to 20 pouches per can in the fourth quarter.
    Philip Morris International dbAccess conference release, 2 June 2026 - the RBH impairment and ZYN ULTRA. — June 2026 · publ. 2 June 2026 · source ↗
  2. ReportedIn June 2026 it launched ZYN ULTRA, in 9mg and 11mg strengths, with 20 pouches per can and a lower price per pouch, and it planned to move its 3mg and 6mg dry ZYN to 20 pouches per can in the fourth quarter.
    Philip Morris International Barclays conference slides, 8 September 2026 - ZYN can format changes. — September 2026 · publ. 8 September 2026 · source ↗
  3. ReportedThe American segment's adjusted gross margin was 65.4% in the second quarter of 2026, down 6.0 points, and segment gross profit fell 9.2% to $555 million on revenue down 0.7%.
    Philip Morris International second-quarter 2026 results release, Form 8-K exhibit 99.1 - volumes, shares, ZYN and 2026 guidance - results, margins, operating companies income, cash and 2026 guidance. — Q2 2026 · publ. 22 July 2026 · source ↗
  4. ReportedThe American segment's adjusted gross margin was 65.4% in the second quarter of 2026, down 6.0 points, and segment gross profit fell 9.2% to $555 million on revenue down 0.7%.
    Philip Morris International Form 10-Q for the quarter ended 30 June 2026 - segment results, the balance sheet, FDA authorisations and shares outstanding. — Q2 2026 · publ. 24 July 2026 · source ↗
  5. ReportedThe segment's gross profit in the first half of 2026 was $935 million, down 27.9%, a steeper fall than revenue's 16.1%.
    Philip Morris International Form 10-Q for the quarter ended 30 June 2026 - segment results, the balance sheet, FDA authorisations and shares outstanding. — Q2 2026 · publ. 24 July 2026 · source ↗
  6. ReportedThe segment's gross profit in the first half of 2026 was $935 million, down 27.9%, a steeper fall than revenue's 16.1%.
    Philip Morris International Form 10-Q for the quarter ended 30 June 2026 - segment results, the balance sheet, FDA authorisations and shares outstanding. — Q2 2026 · publ. 24 July 2026 · source ↗
Sources
Generated September 26, 2026